1 Min Read
July 18 (Reuters) - Bayer AG : * Says two-year results from Phase III trial of Eylea eye drug show sustained improvement in vision for people with diabetic macular edema
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.